Premium
Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project
Author(s) -
Ritchie Karen,
Ropacki Michael,
Albala Bruce,
Harrison John,
Kaye Jeffrey,
Kramer Joel,
Randolph Christopher,
Ritchie Craig W.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.154
Subject(s) - dementia , cognition , cognitive decline , normative , psychology , population , disease , alzheimer's disease , clinical trial , medicine , biomarker , clinical psychology , psychiatry , pathology , political science , environmental health , biochemistry , chemistry , law
The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large‐scale proof‐of‐concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross‐cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.